Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

This study tests whether ponatinib (a targeted cancer drug) can help people with chronic myeloid leukemia (CML — a type of blood cancer) who have not responded to or cannot tolerate other standard targeted therapies. **You may be eligible if...** - You have CML in its early (chronic) phase confirmed by specific genetic tests - Your cancer has not responded well to at least one standard targeted therapy (such as dasatinib, nilotinib, or bosutinib) - You are older than 18 and in reasonably good health - Your liver and kidney function tests are within acceptable limits - You are willing to use effective contraception during the study **You may NOT be eligible if...** - You have received more than one approved targeted therapy for CML, or any non-approved targeted therapy - You have serious heart or blood vessel disease (history of heart attack, stroke, blood clots, severe heart failure) - You have uncontrolled high blood pressure, poorly controlled diabetes (HbA1c over 7.5%), or active serious psychiatric illness - You are pregnant or breastfeeding - You have a history of pancreatitis (inflamed pancreas) within the past year - Your CML has advanced to a blast or accelerated phase Talk to your doctor to see if this trial is right for you.